Among the many ways Trump has shattered White House norms, his impulsive public communications rank among the most consequential. By inspiring investors or spooking them, his...Politicsread more
A federal judge in New York City on Wednesday said Deutsche Bank and Capital One can turn over financial documents related to President Donald Trump and his businesses in...Politicsread more
CNEX, backed by Microsoft and Dell, filed new allegations in a Texas suit accusing China's Huawei and an executive of trade secrets theft.Technologyread more
In a private call with Morgan Stanley clients on Wednesday, research analyst Adam Jones, a long-time Tesla bull, said it's extremely unlikely that big tech firms like Apple or...Technologyread more
Shares of L Brands, the owner of Victoria's Secret and Bath & Body Works, rose nearly 11% in aftermarket trading Wednesday after the company reported it beat revenue and...Retailread more
Officials remained firmly committed to a "patient" policy stance at their meeting earlier this month.The Fedread more
The president may have more success in the court fights to come, including appeals in the cases decided this week. But the two losses are nonetheless a dramatic setback for...Politicsread more
"Target's gutsy decision to make its stores the centerpiece of its fulfillment system has turned out to be a brilliant move," Jim Cramer says.Mad Money with Jim Cramerread more
A slew of retail earnings the past two weeks makes it clear that while Americans continue to shop, they aren't ringing registers at department stores.Retailread more
Talk about 5G is everywhere right now, from the trade war with China to the ban on Huawei. Here's what 5G is and why it matters.Technologyread more
Stocks that would benefit from a federal infrastructure spending program fell after President Trump ended a meeting on infrastructure spending with Democratic leaders.Market Insiderread more
Parexel International, a global biopharmaceutical services provider, will be acquired by Pamplona Capital Management, the two companies announced Tuesday.
The private equity firm was said to be nearing a deal to buy contract drug research firm Parexel for $4.6 billion, the Wall Street Journal reported earlier Tuesday morning.
In a press release, Parexel confirmed it will be acquired by Pamplona for $88.10 per share in cash, in a transaction valued at approximately $5 billion, which includes the pharmaceutical company's net debt.
This purchase price represents a nearly 28 percent premium to Parexel's closing stock price on May 5, the last trading day prior to published market speculation on the deal going through.
Shares of Parexel closed Monday at $83.92 apiece. The stock was climbing about 4 percent in premarket trading Tuesday following news of this deal.
"Today's announcement is the culmination of a comprehensive review of the opportunities available to the Company, including interest solicited and received from multiple parties with the assistance of independent financial and legal advisors," Parexel CEO Josef von Rickenbach said in a statement.
"Having considered these opportunities, the [Parexel] Board of Directors unanimously determined that this all-cash transaction and the significant, certain value it provides is in the best interest of [Parexel] shareholders, as well as our company. "
Activist investors, including Starboard Value, have reportedly been putting pressure on Parexel to explore a sale, arguing the company's profit margins are weak.
On Tuesday, Parexel said the acquisition by Pamplona is expected to close early in the fourth quarter of 2017.
Upon completion of the transaction, Parexel will become a privately held company, and its common stock will no longer be listed on any public market.
Boston-based Parexel provides a range of services to the pharmaceutical industry, ranging from drug development and regulatory consulting, to clinical pharmacology, clinical trials management, and reimbursement.
—Reuters contributed to this reporting.